ALL Clinical Trial
Official title:
Massage Therapy vs. Music Therapy vs. Usual Care in an Inpatient Setting: A Pilot Study
Verified date | January 2015 |
Source | Boston Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This project studies the feasibility of (1) implementing massage therapy and music therapy onto a busy medical inpatient unit at Boston Medical Center, and (2) evaluating massage therapy and music therapy's impact on patient satisfaction, patient outcomes, and cost. The investigators will conduct a randomized controlled trial comparing massage therapy, music therapy, and usual care to collect preliminary data on critical outcomes for patients (satisfaction, symptom control) and for the hospital (pain medication use and length of stay, both critical drivers of cost). The investigators anticipate using these preliminary data to apply for a future larger and longer adequately powered randomized controlled trial to definitively answer the following research questions: does implementation of an inpatient massage therapy and/or music therapy service (a) improve patient satisfaction; (b) reduce symptoms such as pain; and (c) lower health care costs through less pain medication and reduced length of stay?
Status | Completed |
Enrollment | 90 |
Est. completion date | January 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years or older - Inpatient on the Boston Medical C enter Family Medicine inpatient service Exclusion Criteria: - Inability to provide informed consent - Contagious skin disease or infection - Hemophilia - Thrombocytopenia - Encephalopathy - Dementia - Altered mental status - 1:1 status (requiring constant supervision) - Any condition, as determined by the attending physician, which would prevent participation in the study. - Observation status |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Country | Name | City | State |
---|---|---|---|
United States | Boston Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Boston Medical Center | Berklee College of Music, Muscular Therapy Institute Foundation, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient satisfaction | Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey questions | within 7 days after discharge | No |
Secondary | Pain medication use | Administration of pain medication is documented in the electronic medical record each time a dose is given. We will use the EMR to document number of doses and amount (mg) of each dose during the participant's stay. | duration of hospital stay, an expected average of 4 days | No |
Secondary | Sedative use | Administration of sedatives is documented in the electronic medical record each time a dose is given. We will use the EMR to document number of doses and amount (mg) of each dose during the participant's stay. | duration of hospital stay, an expected average of 4 days | No |
Secondary | Length of stay | duration of hospital stay, an expected average of 4 days | No | |
Secondary | Number of re-admissions 30 days after initial discharge | 30 days post-discharge | No | |
Secondary | Pain level | Pain levels are documented for every patient by nurses on a daily basis. We will utilize the electronic medical record (EMR) and document every pain evaluation (0-10 point scale of current pain intensity) performed by nurses on inpatient unit during participant's stay. | duration of hospital stay, an expected average of 4 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
Terminated |
NCT01230788 -
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05461625 -
ACL Reconstruction With/Without ALL Reconstruction
|
N/A | |
Recruiting |
NCT02990572 -
Amish/Mennonite Research Contact Registry
|
||
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Recruiting |
NCT04601584 -
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05592470 -
commd7 Gene Expression in ALL
|
||
Recruiting |
NCT02861209 -
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
|
N/A | |
Completed |
NCT01012492 -
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
|
Phase 2 | |
Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT03571321 -
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
|
Phase 1 | |
Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
Active, not recruiting |
NCT03154346 -
Project Baseline Health Study
|
||
Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
Completed |
NCT01319864 -
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
|
Phase 1 |